TY - JOUR AU - Trudeau, M. E. AU - Eisenhauer, E. A. AU - Higgins, B. AU - Letendre, F. AU - Lofters, W. S. AU - Norris, B. AU - Vandenberg, T. AU - Delorme, F. AU - Muldal, A. PY - 1996 DA - 1996// TI - Docetaxel in patients with metastic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. JO - J Clin Oncol VL - 14 UR - https://doi.org/10.1200/JCO.1996.14.2.422 DO - 10.1200/JCO.1996.14.2.422 ID - Trudeau1996 ER - TY - JOUR AU - Trudeau, M. E. AU - Crump, M. AU - Latreille, J. AU - Pritchard, K. I. AU - Palmer, M. AU - Tu, D. AU - Shepherd, L. AU - Shear, N. AU - Shapiro, L. AU - Oldfield, S. PY - 1999 DA - 1999// TI - Escalating doses of docetaxel and epirubicin as first line therapy for metastatic breast cancer: a phase I/II study of the National Cancer Institute of Canada Clinical Trials Group [abstract]. JO - Pro Am Soc Clin Oncol VL - 18 ID - Trudeau1999 ER - TY - JOUR AU - Trudeau, M. E. AU - Crump, M. AU - Latreille, J. AU - Pritchard, K. I. AU - Palmer, M. AU - Tu, D. AU - Shepherd, L. AU - Shear, N. AU - Shapiro, L. AU - Oldfield, S. PY - 1999 DA - 1999// TI - Escalating doses of docetaxel and epirubicin as first line therapy for metastatic breast cancer: A phase I/II study of the National Cancer Institute of Canada – Clinical Trials Group [abstract 443]. JO - Proc Am Soc Clin Oncol VL - 18 ID - Trudeau1999 ER - TY - JOUR AU - Parissenti, A. M. AU - Gannon, B. R. AU - Villeneuve, D. J. AU - Kirwan-rhude, A. F. AU - Chadderton, A. AU - Gluck, S. PY - 1999 DA - 1999// TI - Lack of modulation of MDR1 gene expression by dominant inhibition of cAMP-dependent protein kinase in doxorubicin-resistant MCF-7 breast cancer cells. JO - Int J Cancer VL - 82 UR - https://doi.org/3.0.CO;2-8 DO - 3.0.CO;2-8 ID - Parissenti1999 ER - TY - JOUR AU - Goss, P. E. AU - Ingle, J. N. AU - Martino, S. AU - Robert, N. J. AU - Muss, H. B. AU - Piccart, M. J. AU - Castiglione, M. AU - Tu, D. AU - Shepherd, L. AU - Pater, J. L. PY - 2004 DA - 2004// TI - Updated analysis of the NCIC CTG Ma.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer [abstract. JO - Proc Am Soc Clin Oncol VL - 22 ID - Goss2004 ER - TY - JOUR AU - Goss, P. E. AU - Ingle, J. N. AU - Martino, S. AU - Robert, N. J. AU - Muss, H. B. AU - Piccart, M. J. AU - Castiglione, M. AU - Tu, D. AU - Shepherd, L. AU - Pritchard, K. I. PY - 2003 DA - 2003// TI - A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. JO - N Eng J Med VL - 349 UR - https://doi.org/10.1056/NEJMoa032312 DO - 10.1056/NEJMoa032312 ID - Goss2003 ER - TY - JOUR PY - 2002 DA - 2002// TI - Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. JO - Lancet VL - 359 UR - https://doi.org/10.1016/S0140-6736(02)09088-8 DO - 10.1016/S0140-6736(02)09088-8 ID - ref7 ER - TY - JOUR PY - 2003 DA - 2003// TI - Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. JO - Cancer VL - 98 UR - https://doi.org/10.1002/cncr.11745 DO - 10.1002/cncr.11745 ID - ref8 ER - TY - JOUR AU - Boccardo, F. AU - Rubagotti, A. AU - Amoroso, D. AU - Mesiti, M. AU - Massobrio, M. AU - Benedetto, C. AU - Porpiglia, M. AU - Rinaldini, M. AU - Paladini, G. AU - Distante, V. PY - 2004 DA - 2004// TI - Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. JO - Breast Cancer Res Treat VL - 85 ID - Boccardo2004 ER - TY - JOUR AU - Coombes, R. C. AU - Hall, E. AU - Gibson, L. AU - Paridaens, R. AU - Jassem, J. AU - Delozier, T. AU - Jones, S. E. AU - Alvarez, I. AU - Bertelli, G. AU - Ortmann, O. PY - 2004 DA - 2004// TI - A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. JO - N Eng J Med VL - 350 UR - https://doi.org/10.1056/NEJMoa040331 DO - 10.1056/NEJMoa040331 ID - Coombes2004 ER - TY - JOUR AU - Ragaz, J. AU - Stewart, D. J. AU - Le, N. AU - Plenderleith, I. H. AU - Spinelli, J. J. AU - Basco, V. E. AU - Wilson, K. S. AU - Knowling, M. A. AU - Coppin, C. M. AU - Paradis, M. PY - 1997 DA - 1997// TI - Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. JO - N Engl J Med VL - 337 UR - https://doi.org/10.1056/NEJM199710023371402 DO - 10.1056/NEJM199710023371402 ID - Ragaz1997 ER - TY - JOUR AU - Overgaard, M. AU - Hansen, P. S. AU - Overgaard, J. AU - Rose, C. AU - Andersson, M. AU - Bach, F. AU - Kjaer, M. AU - Gadeberg, C. C. AU - Mouridsen, H. T. AU - Jensen, M. B. PY - 1997 DA - 1997// TI - Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. JO - N Engl J Med VL - 337 UR - https://doi.org/10.1056/NEJM199710023371401 DO - 10.1056/NEJM199710023371401 ID - Overgaard1997 ER -